Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NeoStem to Acquire Progenitor for $20 Million of Stock

publication date: Sep 24, 2010
NeoStem has signed a definitive agreement to acquire Progenitor Cell Therapy, LLC, a US cell therapy service company. NeoStem, which did not address the question of whether it would offer Progenitor's services in China, said the transaction will be immediately accretive to earnings. NeoStem will issue 11.2 million shares and warrants to purchase between 1 million to 3 million additional shares to the current owners of Progenitor, giving the deal a value of about $20 million. More details....

Stock Symbol: (NYSE Amex: NBS)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here